Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Continuing Dismay In Alzheimer's: vTv's RAGE Antagonist Fails In Phase III Study

Executive Summary

A further mechanism of action has proven ineffective in top-line data from a late-stage study in Alzheimer's disease, adding to the long list of tried and failed approaches to the seemingly intractable condition.

You may also be interested in...



M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.

Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D

Boehringer's investigational drug, BI 409306, is the second big pharma PDE9 inhibitor to fail in Alzheimer's clinical trials; Eisai is still standing with a Phase I compound but the odds are not in its favor.

What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today

The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel